Activity of botulinum toxin type A in cranial dura: Implications for treatment of migraine and other headaches

British Journal of Pharmacology

Volumn 173, Issue 2, 2016, Pages 279-291

  Lackovic, Zdravko ^a   Filipovic, Boris ^a   Matak, Ivica ^a,b   Helyes, Zsuzsanna ^c  

^a UNIVERSITY OF ZAGREB   (Croatia)

^b University Hospital Sveti Duh   (Croatia)

^c UNIVERSITY OF PÉCS   (Hungary)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN A; MUSCLE RELAXANT AGENT;

ANIMAL; DRUG EFFECTS; DURA MATER; HEADACHE; MALE; METABOLISM; MIGRAINE DISORDERS; PATHOLOGY; RAT; SKULL; TREATMENT OUTCOME; WISTAR RAT;

ANIMALS; BOTULINUM TOXINS, TYPE A; DURA MATER; HEADACHE; MALE; MIGRAINE DISORDERS; NEUROMUSCULAR AGENTS; RATS; RATS, WISTAR; SKULL; TREATMENT OUTCOME;

EID: 84953346676     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13366     Document Type: Article

References (56)

1. Akerman S, Holland PR, Hoffmann J, (2013). Pearls and pitfalls in experimental in vivo models of migraine: dural trigeminovascular nociception. Cephalalgia 33: 577-592.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al., (2013). The concise guide to PHARMACOLOGY 2013/14: G protein-coupled receptors. Br J Pharmacol 170: 1459-1581.
3. Arulmani U, Gupta S, VanDenBrink AM, Centuriõn D, Villalõn CM, Saxena PR, (2006). Experimental migraine models and their relevance in migraine therapy. Cephalalgia 26: 642-659.
4. Bellamy JL, Cady RK, Durham PL, (2006). Salivary levels of CGRP and VIP in rhinosinusitis and migraine patients. Headache 46: 24-33.
5. Bevilaqua Grossi D, Lipton RB, Bigal ME, (2009). Temporomandibular disorders and migraine chronification. Curr Pain Headache Rep 13: 314-318.
6. Bigal ME, Walter S, Rapoport AM, (2013). Calcitonin gene-related peptide (CGRP) and migraine current understanding and state of development. Headache 53: 1230-1244.
7. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, de Camilli P, et al., (1993). Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 365: 160-163.
8. Burstein R, Zhang X, Levy D, Aoki KR, Brin MF, (2014). Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: therapeutic implications for migraine and other pains. Cephalalgia 34: 853-869.
9. Buzzi MG, Moskowitz MA, (1990). The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 99: 202-206.
10. Cangiano A, Fried JA, (1977). The production of denervation-like changes in rat muscle by colchicine, without interference with axonal transport or muscle activity. J Physiol 265: 63-84.
11. Cernuda-Morollõn E, Martínez-Camblor P, Ramõn C, Larrosa D, Serrano-Pertierra E, Pascual J, (2014). CGRP and VIP levels as predictors of efficacy of onabotulinumtoxin type A in chronic migraine. Headache 54: 987-995.
12. Cernuda-Morollõn E, Ramõn C, Martínez-Camblor P, Serrano-Pertierra E, Larrosa D, Pascual J, (2015). OnabotulinumtoxinA decreases interictal CGRP plasma levels in chronic migraine patients. Pain 156: 820-824.
13. Dallas FA, Dixon CM, McCulloch RJ, Saynor DA, (1989). The kinetics of 14C-GR43175 in rat and dog. Cephalalgia 9: 53-56.
14. de Rossi SS, Greenberg MS, Liu F, Steinkeler A, (2014). Temporomandibular disorders: evaluation and management. Med Clin North Am 98: 1353-1384.
15. Diener HC, Dodick DW, Aurora SK, Turkel CC, Degryse RE, Lipton RB, et al., (2010). PREEMPT 2 Chronic Migraine Study Group. OnabotulinumtoxinA for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30: 804-814.
16. Dressler D, (2013). Botulinum toxin therapy: its use for neurological disorders of the autonomic nervous system. J Neurol 260: 701-713.
17. Durham PL, (2008). Inhibition of calcitonin gene-related peptide function: a promising strategy for treating migraine. Headache 48: 1269-1275.
18. Durham PL, Russo AF, (1999). Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci 19: 3423-3429.
19. Edvinsson L, (2015). CGRP receptor antagonists and antibodies against CGRP and its receptor in migraine treatment. Br J Clin Pharmacol. doi: 10.1111/bcp.12618.
20. Edvinsson L, Warfvinge K, (2013). CGRP receptor antagonism and migraine therapy. Curr Protein Pept Sci 14: 386-392.
21. Filipovic B, Matak I, Bach-Rojecky L, Lackovic Z, (2012). Central action of peripherally applied botulinum toxin type A on pain and dural protein extravasation in rat model of trigeminal neuropathy. PLoS One 7: e29803.
22. Filipovic B, Matak I, Lackovic Z, (2014). Dural neurogenic inflammation induced by neuropathic pain is specific to cranial region. J. Neural Transm 121: 555-563.
23. Franco AL, Gonçalves DA, Castanharo SM, Speciali JG, Bigal ME, Camparis CM, (2010). Migraine is the most prevalent primary headache in individuals with temporomandibular disorders. J Orofac Pain 24: 287-292.
24. Geppetti P, Rossi E, Chiarugi A, Benemei S, (2012). Antidromic vasodilatation and the migraine mechanism. J. Headache Pain 13: 103-111.
25. Goadsby PJ, Edvinsson L, Ekman R, (1990). Vasoactive peptide release in the extracerebral circulation of humans during migraine headache. Ann Neurol 28: 183-187.
26. Göbel H, Czech N, Heinze-Kuhn K, Heinze A, Brenner W, Muhle C, et al., (2000). Evidence of regional plasma protein extravagation in cluster headache using Tc-99 m albumin SPECT. Cephalalgia 20: 287.
27. Harper RP, Kerins CA, McIntosh JE, Spears R, Bellinger LL, (2001). Modulation of the inflammatory response in the rat TMJ with increasing doses of complete Freund's adjuvant. Osteoarthritis Cartilage 9: 619-624.
28. Kalandakanond S, Coffield JA, (2001). Cleavage of SNAP-25 by botulinum toxin type A requires receptor-mediated endocytosis, pH-dependent translocation, and zinc. J. Pharmacol. Exp. Ther. 296: 980-986.
29. Karsan N, Goadsby PJ, (2015). Calcitonin gene-related peptide and migraine. Curr Opin Neurol 28: 250-254.
30. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. PLoS Biol 8: e1000412.
31. Kitamura Y, Matsuka Y, Spigelman I, Ishihara Y, Yamamoto Y, Sonoyama W, et al., (2009). Botulinum toxin type a (150 kDa) decreases exaggerated neurotransmitter release from trigeminal ganglion neurons and relieves neuropathy behaviors induced by infraorbital nerve constriction. Neuroscience 159: 1422-1429.
32. Knotkova H, Pappagallo M, (2007). Imaging intracranial plasma extravasation in a migraine patient: a case report. Pain Med 8: 383-387.
33. Kreutzberg GW, (1969). Neuronal dynamics and axonal flow. IV. Blockage of intra-axonal enzyme transport by colchicine. Proc Natl Acad Sci U S A 62: 722-728.
34. Larrier D, Lee A, (2003). Anatomy of headache and facial pain. Otolaryngol Clin North Am 36: 1041-1053.
35. Markowitz S, Saito K, Moskowitz MA, (1987). Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. J Neurosci 7: 4129-4136.
36. Matak I, Bach-Rojecky L, Filipovic B, Lackovic Z, (2011). Behavioral and immunohistochemical evidence for central antinociceptive activity of botulinum toxin A. Neuroscience 186: 201-207.
37. Matak I, Lackovic Z, (2014). Botulinum toxin A, brain and pain. Prog Neurobiol 119-120: 39-59.
38. Matak I, Rossetto O, Lackovic Z, (2014). Botulinum toxin type A selectivity for certain types of pain is associated with capsaicin-sensitive neurons. Pain 155: 1516-1526.
39. Moskowitz MA, (1990). Basic mechanisms in vascular headache. Neurol Clin 8: 801-815.
40. Nelson DL, Phebus LA, Johnson KW, Wainscott DB, Cohen ML, Calligaro DO, et al., (2010). Preclinical pharmacological profile of the selective 5-HT1F receptor agonist lasmiditan. Cephalalgia 30: 1159-1169.
41. Németh J, Görcs T, Helyes Z, Oroszi G, Kocsy T, Pintér E, et al., (1998). Development of a new sensitive CGRP radioimmunoassay for neuropharmacological research. Neurobiology (Bp). 6: 473-475.
42. O'Shaughnessy CT, Connor HE, (1994). Investigation of the role of tachykinin NK1, NK2 receptors and CGRP receptors in neurogenic plasma extravasation in rat dura mater. Eur J Pharmacol 263: 193-198.
43. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al., NC-IUPHAR(2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucl. Acids Res. 42 (Database Issue): D1098-D1106.
44. Peroutka SJ, (2005). Neurogenic inflammation and migraine: implications for the therapeutics. Mol Interv 5: 304-311.
45. Pozsgai G, Hajna Z, Bagoly T, Boros M, Kemény Á, Materazzi S, et al., (2012). The role of transient receptor potential ankyrin 1 (TRPA1) receptor activation in hydrogen-sulphide-induced CGRP-release and vasodilation. Eur J Pharmacol 689: 56-64.
46. Ramachandran R, Yaksh TL, (2014). Therapeutic use of botulinum toxin in migraine: mechanisms of action. Br J Pharmacol 171: 4177-4192.
47. Restani L, Antonucci F, Gianfranceschi L, Rossi C, Rossetto O, Caleo M, (2011). Evidence for anterograde transport and transcytosis of botulinum neurotoxin A (BoNT/A). J Neurosci 31: 15650-15659.
48. Restani L, Novelli E, Bottari D, Leone P, Barone I, Galli-Resta L, et al., (2012). Botulinum neurotoxin A impairs neurotransmission following retrograde transynaptic transport. Traffic 13: 1083-1089.
49. Schueler M, Messlinger K, Dux M, Neuhuber WL, de Col R, (2013). Extracranial projections of meningeal afferents and their impact on meningeal nociception and headache. Pain 154: 1622-1631.
50. Schuh-Hofer S, Boehnke C, Reuter U, Siekmann W, Lindauer U, Arnold G, et al., (2003). A fluorescence-based method to assess plasma protein extravasation in rat dura mater using confocal laser scanning microscopy. Brain Res Brain Res Protoc 12: 77-82.
51. Shimizu T, Shibata M, Toriumi H, Iwashita T, Funakubo M, Sato H, et al., (2012). Reduction of TRPV1 expression in the trigeminal system by botulinum neurotoxin type-A. Neurobiol Dis 48: 367-378.
52. Sunil Dutt C, Ramnani P, Thakur D, Pandit M, (2015). Botulinum toxin in the treatment of muscle specific Oro-facial pain: a literature review. J Maxillofac Oral Surg 14: 171-175.
53. Thalakoti S, Patil VV, Damodaram S, Vause CV, Langford LE, Freeman SE, et al., (2007). Neuron-glia signaling in trigeminal ganglion: implications for migraine pathology. Headache 47: 1008-1023.
54. Villa G, Ceruti S, Zanardelli M, Magni G, Jasmin L, Ohara PT, et al., (2010). Temporomandibular joint inflammation activates glial and immune cells in both the trigeminal ganglia and in the spinal trigeminal nucleus. Mol Pain 6: 89.
55. Williamson DJ, Hargreaves RJ, (2001). Neurogenic inflammation in the context of migraine. Microsc Res Tech 53: 167-178.
56. Zimmerman M, (1983). Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.